Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted18F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern

被引：2

作者：

Yin, Yafu ^{[1
,4
]}

Paller, Channing J. ^{[2
]}

Pomper, Martin G. ^{[1
,2
,3
]}

Pienta, Kenneth J. ^{[2
,3
]}

Gorin, Michael A. ^{[1
,2
,3
]}

Rowe, Steven P. ^{[1
,3
]}

机构：

[1] Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Sch Med, Baltimore, MD USA

[2] Johns Hopkins Univ, Sidney Kimmell Comprehens Canc Ctr, Dept Oncol, Sch Med, Baltimore, MD USA

[3] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Dept Urol, Baltimore, MD USA

[4] China Med Univ, Hosp 1, Dept Nucl Med, Shenyang, Liaoning, Peoples R China

来源：

WORLD JOURNAL OF NUCLEAR MEDICINE | 2019年 / 18卷 / 04期

基金：

美国国家卫生研究院;

关键词：

18F-DCFPyL; positron emission tomography; computed tomography; prostate cancer; prostate-specific membrane; vas deferens;

D O I：

10.4103/wjnm.WJNM_50_18

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

New radiotracers for positron emission tomography imaging that target prostate-specific membrane antigen (PSMA) have emerged as important clinical tools for imaging prostate cancer (PCa). PSMA-targeted radiotracers have demonstrated high sensitivity and high specificity for detecting sites of PCa and are demonstrably superior to conventional imaging modalities such as computed tomography and bone scan. Vas deferens invasion is a rarely encountered poor prognostic feature of PCa. In this case report, we describe a novel pattern of radiotracer uptake in a patient with PCa imaged with PSMA-targeted18F-DCFPyL positron emission tomography/computed tomography that is consistent with diffuse vas deferens involvement.

引用

页码：424 / 427

页数：4

共 50 条

[31] Role of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) in staging [J].

Kesch, Claudia ;

Franiel, Tobias ;

Berliner, Christoph ;

Fendler, Wolfgang P. ;

Herrmann, Ken ;

Hadaschik, Boris .

UROLOGIE, 2025, :220-228

[32] Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma [J].

Udovicich, Cristian ;

Callahan, Jason ;

Bressel, Mathias ;

Ong, Wee Loon ;

Perera, Marlon ;

Tran, Ben ;

Azad, Arun ;

Haran, Shankar ;

Moon, Daniel ;

Chander, Sarat ;

Shaw, Mark ;

Eapen, Renu ;

Goad, Jeremy ;

Lawrentschuk, Nathan ;

Murphy, Declan G. ;

Hofman, Michael ;

Siva, Shankar .

EUROPEAN UROLOGY OPEN SCIENCE, 2022, 44 :60-68

[33] Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study [J].

Gorin, Michael A. ;

Rowe, Steven P. ;

Patel, Hiten D. ;

Vidal, Igor ;

Mana-ay, Margarita ;

Javadi, Mehrbod S. ;

Solnes, Lilja B. ;

Ross, Ashley E. ;

Schaeffer, Edward M. ;

Bivalacqua, Trinity J. ;

Partin, Alan W. ;

Pienta, Kenneth J. ;

Szabo, Zsolt ;

De Marzo, Angelo M. ;

Pomper, Martin G. ;

Allaf, Mohamad E. .

JOURNAL OF UROLOGY, 2018, 199 (01) :126-132

[34] Intraductal Prostate Cancer Affinity for Lymphatic-Predominant Metastases Through 18F-DCFPyL?Prostate-Specific Membrane Antigen?Positron Emission Tomography/CT Scans in Pretreatment Prostate Cancer Patients Reply [J].

Bernardino, Rui ;

Sayyid, Rashid K. ;

Lajkosz, Katherine ;

Al-Daqqaq, Zizo ;

Tiwari, Raj ;

Cockburn, Jessica ;

Leao, Ricardo ;

Metser, Ur ;

Berlin, Alejandro ;

van der Kwast, Theodorus ;

Fleshner, Neil E. .

JOURNAL OF UROLOGY, 2024, 211 (04) :595-595

[35] Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer [J].

Bukavina, Laura ;

Luckenbaugh, Amy N. ;

Hofman, Michael S. ;

Hope, Tom ;

Kamran, Sophia C. ;

Murphy, Declan G. ;

Yamoah, Kosj ;

Ost, Piet .

EUROPEAN UROLOGY, 2023, 83 (06) :521-533

[36] Prostate-specific membrane antigen (PSMA)-ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer [J].

Tateishi, Ukihide .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (04) :349-356

[37] New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography [J].

Afaq, Asim ;

Batura, Deepak ;

Bomanji, Jamshed .

INTERNATIONAL UROLOGY AND NEPHROLOGY, 2017, 49 (05) :803-810

[38] New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography [J].

Asim Afaq ;

Deepak Batura ;

Jamshed Bomanji .

International Urology and Nephrology, 2017, 49 :803-810

[39] The oncological characteristics of non-prostate-specific membrane antigen (PSMA)-expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed tomography [J].

Veerman, Hans ;

Donswijk, Maarten ;

Bekers, Elise ;

Bodar, Yves J. L. ;

Meijer, Dennie ;

van Moorselaar, R. Jeroen A. ;

Oprea-Lager, Daniela E. ;

van Der Noort, Vincent ;

van Leeuwen, Pim J. ;

Vis, Andre N. ;

van der Poel, Henk G. .

BJU INTERNATIONAL, 2022, 130 (06) :750-753

[40] Synthesis and positron emission tomography evaluation of 18F-Glu-Urea-Lys, a prostate-specific membrane antigen-based imaging agent for prostate cancer [J].

Fan, Weiwei ;

Zhang, Zhiwei ;

Zhu, Zheng ;

Yang, Deyong ;

Chen, Xiaochi ;

Wang, Jianbo ;

Chen, Feng ;

Song, Xishuang .

ONCOLOGY LETTERS, 2015, 10 (04) :2299-2302

← 1 2 3 4 5 →